Breaking News Instant updates and real-time market news.

NFLX

Netflix

$227.58

7.12 (3.23%)

, TRV

Travelers

$145.27

5.92 (4.25%)

12:10
01/23/18
01/23
12:10
01/23/18
12:10

On The Fly: Top stock stories at midday

Stocks opened little changed and the Dow and S&P 500 have mostly remained that way all morning. The exception is the Nasdaq, which is extending its rally, helped in large part by the post-earnings jump in Netflix (NFLX). ECONOMIC EVENTS: In the U.S., the Richmond Fed manufacturing index slumped 6 points to a reading of 14 in January. Additionally, the IMF raised its global GDP growth forecast to 3.9% in both 2018 and 2019, due in large part to the U.S. tax bill. In Asia, the Bank of Japan left its monetary policy unchanged, as was widely expected. COMPANY NEWS: Shares of Netflix have advanced over 10% after the company's domestic and international subscriber additions last quarter, and its forecast for membership growth in the new quarter, came in well ahead of consensus... Four Dow members reported earnings this morning. Among them, Travelers (TRV) has been the best performer following its report, rising 4%. Verizon (VZ) was near the bottom of the 30-member group, sliding about a half a percentage point following its worse than expected earnings report, but it was still faring better than the two laggards - Johnson & Johnson (JNJ) and Procter & Gamble (PG) - which each fell about 3%... Tesla (TSLA) announced a new long-term performance award for Chief Executive Officer Elon Musk that vests entirely contingent on achieving market capitalization and operational milestones. In order to fully vest, Tesla's market cap will have to grow to $650B, an increase of almost $600B, and certain revenue and profitability goals will also have to be achieved, the company said. Otherwise, the head of the electric carmaker will receive no salary, no cash bonuses and no other guaranteed compensation of any kind. MAJOR MOVERS: Among the notable gainers was ResMed (RMD), which jumped 17% after the company's "significant" Q2 beat prompted upgrades at Needham and Northland. However, Macquarie analyst David Bailey downgraded ResMed to Underperform, citing valuation and ongoing average selling price declines. Also higher was Whirlpool (WHR), which gained over 2.5% after the Trump Administration established a tariff of up to 50% on imports of large residential washing machines. Among the noteworthy losers was Insmed (INSM), which dropped 6% after the company filed to sell $300M in convertible senior notes. Also lower was Twitter (TWTR), which slipped nearly 2% after the microblog operator confirmed that its chief operating officer, Anthony Noto, will leave to join online lender SoFi as its CEO. INDEXES: Near midday, the Dow was down 19.80, or 0.08%, to 26,194.80, the Nasdaq was up 40.52, or 0.55%, to 7,448.55, and the S&P 500 was up 4.18, or 0.15%, to 2,837.15.

NFLX

Netflix

$227.58

7.12 (3.23%)

TRV

Travelers

$145.27

5.92 (4.25%)

VZ

Verizon

$53.31

-0.15 (-0.28%)

JNJ

Johnson & Johnson

$143.58

-4.565 (-3.08%)

PG

Procter & Gamble

$89.11

-2.78 (-3.03%)

TSLA

Tesla

$351.56

1.54 (0.44%)

RMD

ResMed

$103.82

16.306 (18.63%)

WHR

Whirlpool

$171.12

4.47 (2.68%)

TWTR

Twitter

$22.96

-0.36 (-1.54%)

INSM

Insmed

$30.86

1.58 (5.40%)

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 30

    Jan

  • 07

    Feb

  • 08

    Feb

  • 16

    Feb

  • 28

    Feb

  • 08

    Mar

NFLX Netflix
$227.58

7.12 (3.23%)

01/23/18
01/23/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Netflix (NFLX) downgraded to Neutral from Buy at Buckingham with analyst Matthew Harrigan citing valuation. 2. GoPro (GPRO) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Yuuji Anderson arguing that the market is giving too much credit to the company for its strategic value. 3. Wayfair (W) downgraded to Hold from Buy at Stifel with analyst Scott Devitt citing his view that the risk/reward is balanced at the stock's current levels. 4. Fortinet (FTNT) downgraded to Hold from Buy at Deutsche Bank with analyst Gray Powell saying his field discussions indicate the company's growth in the fourth quarter was weaker than expected. 5. Sprint (S) downgraded to Underperform from Neutral at Macquarie with analyst Amy Young saying she believes Sprint is stuck between a slowdown in the multi-year turnaround and a lack of near-term strategic options as circumstances have deteriorated with rising competition, executive turnover, and increasing capital expenditures. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/23/18
FBCO
01/23/18
NO CHANGE
Target $266
FBCO
Neutral
Netflix price target raised to $266 from $224 at Credit Suisse
Credit Suisse analyst Stephen Ju raised his price target for Netflix to $266 from $224 after quarterly results, saying it is continuing to reap the benefits of its content win streak. The analyst reiterates a Neutral rating on the shares.
01/23/18
BERN
01/23/18
NO CHANGE
Target $302
BERN
Outperform
Netflix price target raised to $302 from $230 at Bernstein
Bernstein analyst Todd Juenger raised his price target for Netflix to $302 from $230 following quarterly results. The analyst reiterates an Outperform rating on the shares.
01/23/18
BUCK
01/23/18
DOWNGRADE
BUCK
Neutral
Netflix downgraded to Neutral on valuation at Buckingham
Buckingham analyst Matthew Harrigan downgraded Netflix to Neutral from Buy citing valuation and raised its price target to $257 from $251. Harrigan remains confident in Netflix's position as a global streaming leader, but contents continued share momentum depends on market confidence that Netflix's guided $3B-4B in negative 2018 free cash flow will generate superior investment returns.
TRV Travelers
$145.27

5.92 (4.25%)

01/09/18
BOFA
01/09/18
UPGRADE
BOFA
Buy
Travelers upgraded to Buy from Neutral at BofA/Merrill
12/04/17
GSCO
12/04/17
INITIATION
Target $124
GSCO
Sell
Travelers initiated with a Sell at Goldman Sachs
Goldman Sachs analyst Yaron Kinar started Travelers with a Sell rating and $124 price target. The analyst sees the company's liability portfolio experiencing underwriting compression due to rising inflationary trends and weak pricing. Kinar does not believe consensus estimates and valuations appropriately reflect the earnings erosion and rising volatility in the company's commercial liability business.
10/23/17
ARGS
10/23/17
NO CHANGE
Target $145
ARGS
Buy
Travelers price target raised to $145 from $139 at Argus
Argus analyst Jacob Kilstein raised his price target on Travelers to $145 and kept a Buy rating following Q3 results. Kilstein cites upward momentum in share prices, favorable valuation relative to peers, and management's growth initiatives, forecasting gross margin expansion as the company raises prices on auto insurance and expands its data analytics. The analyst is also positive on Travelers shareholder returns, noting the recent 7% dividend hike and a $5B stock buyback.
10/20/17
RBCM
10/20/17
NO CHANGE
Target $140
RBCM
Outperform
Travelers price target raised to $140 from $135 at RBC Capital
RBC Capital analyst Mark Dwelle raised his price target on Travelers to $140 and kept his Outperform rating after Q3 earnings. Dwelle says the company remained profitable in spite of the recent headwinds of hurricane losses and asbestos-related charge. Looking ahead, the analyst expects Travelers margins to compare favorable to peers in 2018 given the management's constructive commentary on pricing trends.
VZ Verizon
$53.31

-0.15 (-0.28%)

01/16/18
01/16/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Underperform from Neutral at Macquarie with analyst Laurent Vasilescu citing weaker North America revenues, flat Connected Fitness revenues, international revenues of up 21% year-over-year, gross margin pressure, and higher SG&A assumptions. 2. Verizon (VZ) downgraded to Neutral from Buy at MoffettNathanson. 3. Lockheed Martin (LMT) and Rockwell Collins (COL) were downgraded to Market Perform from Outperform at Wells Fargo. 4. Spirit Airlines (SAVE) downgraded to Hold from Buy at Stifel with analyst Joseph DeNardi saying he believes Spirit will benefit this year from an improving demand and revenue environment, but that its higher revenue risk relative to potential competitive responses to its expected capacity growth is not fully reflected in the stock at current levels. 5. Finisar (FNSR) downgraded to Sell from Neutral at Goldman Sachs with analyst Doug Clark saying risks of oversupply and competition are heating up in the optical component landscape. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/17/18
01/17/18
DOWNGRADE
Target $55

Equal Weight
With fewer likely buyers seen, Morgan Stanley cuts Dish to Equal Weight
As previously reported, Morgan Stanley analyst Benjamin Swinburne downgraded Dish Network (DISH) to Equal Weight from Overweight as he now sees fewer likely buyers of its assets than hoped. T-Mobile (TMUS) has acquired significant additional spectrum, reducing the potential for a Dish partnership, tax reform will help Verizon (VZ) as it moves further towards small cell deployments in lieu of adding new spectrum, and the FCC is also considering a new auction, Swinburne tells investors. Additionally, the DOJ challenge of AT&T's (T) Time Warner (TWX) deal suggests a more challenging M&A backdrop than assumed for AT&T, which he had viewed as potentially the most logical buyer of Dish's DBS assets, Swinburne added. With Dish beginning to spend on its network in 2018 to boot, Swinburne lowered his price target on the stock to $55 from $75.
01/22/18
HOWW
01/22/18
UPGRADE
HOWW
Outperform
Verizon upgraded to Outperform from Sector Perform at Scotia Howard Weil
01/22/18
01/22/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. U.S. Steel (X) upgraded to Neutral from Sell at Citi with analyst Alexander Hacking saying he sees steel prices better supported near-term and increased his EBITDA estimates. 2. Aflac (AFL) upgraded to Strong Buy from Outperform at Raymond James with analyst Gregory Peters citing relative shares underperformance since the recent article alleging fraud at the company. 3. Schlumberger (SLB) upgraded to Overweight from Neutral at Atlantic Equities. 4. Harley-Davidson (HOG) upgraded to Outperform from Market Perform at Wells Fargo with analyst Timothy Conder saying investors are not appreciating the benefits of tax reform to Harley-Davidson. 5. Verizon (VZ) upgraded to Outperform from Sector Perform at Scotia Howard Weil. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
JNJ Johnson & Johnson
$143.58

-4.565 (-3.08%)

01/18/18
MSCO
01/18/18
NO CHANGE
Target $157
MSCO
Equal Weight
Zytiga ruling a headwind, but doesn't change J&J thesis, says Morgan Stanley
Morgan Stanley analyst David Lewis noted that Johnson & Johnson suffered an adverse Zytiga IPR ruling, which he calls an incremental headwind. However, he added that a possible earlier generic Zytiga entry is irrelevant to his net present value for J&J shares and doesn't change his view that its Pharma growth accelerates in 2018. Lewis keeps an Equal Weight rating and $157 price target on J&J shares.
01/04/18
RBCM
01/04/18
NO CHANGE
Target $54
RBCM
Outperform
Pacira price target raised to $54 from $50 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Pacira (PCRX) to $54 and kept his Outperform rating. Stanicky says his focus is on the company's expected pre-announcement for Q4 this week and his upcoming discussion with CEO Dave Stack on Monday regarding changes from CMS around unbundling of payments that could represent a game changing opportunity for the company's EXPAREL. The analyst notes that traction is building around Pacira's relationship with Johnson & Johnson (JNJ) on the ortho selling side, which marks about half of its revenue.
01/02/18
01/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) downgraded to Neutral from Overweight at JPMorgan with analyst Michael Weinstein saying he sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. 2. PG&E (PCG) downgraded to Sell from Neutral at Guggenheim and to Neutral from Buy at Goldman Sachs. Goldman analyst Michael Lapides saying resolution of claims from the California wildfires, if inverse condemnation is applied, could take years and "cash flow/balance sheet impacts could prove significant still." 3. Allstate (ALL) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying the company's margin expansion story has played out. 4. Cabot Oil & Gas (COG) downgraded two notches to Underperform from Outperform at Raymond James with analyst John Freeman citing valuation after "considerable" 2017 share outperformance. 5. Windstream (WIN) downgraded to Underweight from Neutral at JPMorgan with analyst Philip Cusick saying he sees fundamental business challenges continuing in both the near and long term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/02/18
JPMS
01/02/18
DOWNGRADE
Target $150
JPMS
Neutral
Johnson & Johnson downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Weinstein downgraded Johnson & Johnson (JNJ) to Neutral with an unchanged price target of $150. The stock closed Friday down 81c to $139.72. The analyst sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. He remains "fundamentally bullish" on the company, however. Weinstein this morning upgraded both Abbott Laboratories (ABT) and Baxter International (BAX) to Overweight.
PG Procter & Gamble
$89.11

-2.78 (-3.03%)

12/13/17
DBAB
12/13/17
INITIATION
Target $101
DBAB
Buy
Procter & Gamble initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Steve Powers started Procter & Gamble with a Buy rating and $101 price target. The company is well positioned after "finally" catching up with market realities," the analyst contends. He views the risk/reward as attractive at current share levels.
12/27/17
JEFF
12/27/17
NO CHANGE
JEFF
Nielsen shows improved two-week sales trends, says Jefferies
Jefferies analyst Kevin Grundy says two-week sales growth in U.S. Nielsen channels improved sequentially for key home and personal care companies Colgate-Palmolive (CL), Church & Dwight (CHD) and Clorox (CLX), as well as beverage companies Monster Beverage (MNST), Coca-Cola (KO) and Dr Pepper Snapple (DPS). While overall growth remains tepid, sequential improvement in December for consumer spending, including staples, has been more upbeat, Grundy tells investors in a research note titled "Party Like It's 1999? Not Quite, But US Nielsen HPC/Bevs 2-Week Data Improves." The analyst favors shares of Church & Dwight, Procter & Gamble (PG), Dr Pepper and Monster.
01/16/18
GSCO
01/16/18
UPGRADE
Target $88
GSCO
Neutral
Procter & Gamble upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Jason English upgraded Procter & Gamble to Neutral and raised his price target for the shares to $88 from $83. The analyst no longer sees enough downside to estimates to drive material underperformance for the stock. he admits his expectation of a negative estimate revision cycle has failed to materialize.
01/16/18
01/16/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded to Buy from Neutral at Nomura Instinet with analyst Romit Shah saying with Broadcom's (AVGO) hostile takeover attempt now analogous to a "gun to the head," Qualcomm management is likely to more aggressively focus on driving shareholder value in order to remain a standalone franchise. 2. Twitter (TWTR) upgraded to Buy from Sell at Aegis with analyst Victor Anthony saying he believes 2018 will be an inflection point in owned and operated advertising for Twitter and he sees a return to double-digit growth in that area in 2019. 3. Procter & Gamble (PG) upgraded to Neutral from Sell at Goldman Sachs with analyst Jason English saying he no longer sees enough downside to estimates to drive material underperformance for the stock. 4. Northrop Grumman (NOC) and Curtiss-Wright (CW) were upgraded to Outperform from Market Perform at Wells Fargo. 5. Ciena (CIEN) was upgraded to Buy from Neutral at Goldman Sachs, while Adtran (ADTN) was upgraded to Neutral from Sell. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TSLA Tesla
$351.56

1.54 (0.44%)

01/23/18
FBCO
01/23/18
NO CHANGE
FBCO
30% solar import tariff positive for First Solar, Tesla, says Credit Suisse
Credit Suisse analyst Michael Weinstein notes that President Trump approved solar import tariffs at 30% for crystalline-silicon solar cells and modules, in-line with expectations. The analyst believes the news is positive for companies exempt from the tariff, notably First Solar (FSLR) and Tesla (TSLA) until now. Conversely, Weinstein expects negative sentiment around Chinese solar manufacturers, such as JinkoSolar (JKS) and JA Solar (JASO), and expects negligible impact to residential solar developers Sunrun (RUN) and Vivint Solar (VSLR).
01/08/18
BARD
01/08/18
UPGRADE
Target $152
BARD
Outperform
Albemarle upgraded to Outperform at Baird
As reported previously, Baird analyst Ben Kallo upgraded Albemarle (ALB) to Outperform from Neutral as he sees several upcoming catalysts that could drive the shares higher. Those catalysts include upcoming auto shows, which could display new electric cars that are drivers of lithium demand, potential auto announcements regarding electrification, and an ongoing ramp of Tesla's (TSLA) Model 3. Kallo raised his price target to $152 from $135 on Albemarle shares.
01/04/18
MSCO
01/04/18
NO CHANGE
Target $379
MSCO
Equal Weight
Morgan Stanley says Tesla Model 3 target shift 'should not at all be a surprise'
Morgan Stanley analyst Adam Jonas noted that Tesla posted delivery figures for Q4 that topped his forecast for each model line it offers, including the Model 3, adding that he thinks Tesla pushing out its production target of 5,000 Model 3 per week to the end of Q2 "should not at all be a surprise to the market." Jonas said his Q1 Model 3 delivery forecast of 8,000 units implies a pace of less than 700 per week, but Tesla appears to be currently producing the mass-market car at a pace well ahead of that implied in his earnings model. The analyst, who also noted that the company's Q4 deliveries suggest revenue 10% above his prior forecast, maintains an Equal Weight rating on the shares but said he would "buy the dip" in Tesla if the delayed Model 3 ramp causes weakness.
01/23/18
MSCO
01/23/18
NO CHANGE
MSCO
Equal Weight
Tesla performance plan for Musk a marketing tool, says Morgan Stanley
Morgan Stanley analyst Adam Jonas said he sees Tesla CEO Elon Musk's long-term incentive plan as an "aspirational marketing tool" to attract talent and capital as competition increases in both electric vehicles and autonomous vehicles. The operational targets provide an incentive for Tesla to be a very large company, the plan leaves flexibility for it to find a new CEO and the mega-cap milestones are meant to "capture the spirit of the bull market," said Jonas, who believes the true financial incentive to Musk is open to debate given how he is already "all in" on Tesla. He views the package as more important to investor confidence than to Musk financially, added Jonas, who keeps an Equal Weight rating on the shares.
RMD ResMed
$103.82

16.306 (18.63%)

01/23/18
01/23/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dollar General (DG) upgraded to Outperform from Underperform at Wells Fargo with analyst Edward Kelly saying performance at the company has improved recently, and the momentum should accelerate in 2018. 2. Dick's Sporting (DKS) upgraded to Positive from Neutral at Susquehanna with analyst Sam Poser saying he believes earnings results should surprise to the upside given a low bar and weather that was not as bad as expected, which drove better sales trends. 3. Caterpillar (CAT) upgraded to Buy from Neutral at Seaport Global with analyst Michael Shlisky citing fourth quarter dealer checks and discussions with the company and competitors. 4. ResMed (RMD) upgraded to Hold from Underperform at Needham with analyst Mike Matson saying he now believes the company can sustain higher revenue growth over the next few years and is positioned to drive sustained operating leverage. 5. HP Enterprise (HPE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Katy Huberty saying she believes that declines at the legacy Enterprise Group will moderate in 2018 and be offset by upward trending IT budgets and near-term growth from hyperconverged, flash and network security. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/23/18
NORL
01/23/18
UPGRADE
NORL
Market Perform
ResMed upgraded to Market Perform from Underperform at Northland
01/23/18
MACQ
01/23/18
DOWNGRADE
MACQ
Underperform
ResMed downgraded to Underperform from Neutral at Macquarie
Macquarie analyst David Bailey downgraded ResMed to Underperform citing valuation and ongoing ASP declines.
01/23/18
JEFF
01/23/18
NO CHANGE
Target $75
JEFF
Underperform
ResMed margins continue to deteriorate, says Jefferies
Jefferies analyst Anthony Petrone says a 17c tax benefit drove much of ResMed's Q2 beat while the company's margins continue to deteriorate. Further, underlying sleep growth remains "opaque," Petrone tells investors in a post-earnings research note. The analyst views the company's outlook as unclear and keeps an Underperform rating on the shares. He upped his price target for ResMed to $75 from $60.
WHR Whirlpool
$171.12

4.47 (2.68%)

10/24/17
10/24/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Electric (GE) was downgraded to Hold from Buy at Stifel and to Underperform from Perform at Oppenheimer. 2. Whirlpool (WHR) was downgraded to Sector Perform from Top Pick at RBC Capital and to Neutral from Buy at BofA/Merrill. 3. Roche (RHHBY) downgraded to Hold from Buy at Berenberg with analyst Alistair Campbell saying he sees the company's earnings growth slowing to the slow single digits over the next five years as biosimilar competition ramps. 4. United Continental (UAL) downgraded to Neutral from Overweight at Atlantic Equities with the firm's analyst saying earnings initiatives do not appear to be performing to plan and he is "very skeptical" of United's ability to close the margin gap with Delta (DAL). 5. Hanesbrands (HBI) downgraded to Perform from Outperform at Oppenheimer with analyst Anna Andreeva saying while she remains a fan of "Brands over Retailers" framework, and Hanesbrands has profitability cushions, negative organics domestically take away earnings upside bull case. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/24/17
FBCO
10/24/17
NO CHANGE
Target $187
FBCO
Neutral
Whirlpool price target lowered to $187 from $206 at Credit Suisse
Credit Suisse analyst Susan Maklari lowered her price target for Whirlpool to $187 from $206 as inflation and negative mix shift drive Q3 EPS below expectation. The analyst reiterates a Neutral rating on the shares.
11/15/17
JPMS
11/15/17
NO CHANGE
JPMS
Overweight
Whirlpool view of N.A. industry growth a bit aggresive, says JPMorgan
JPMorgan analyst Michael Rehaut noted that U.S. "AHAM 6" appliance industry shipments fell 1.3% year-over-year in October, which he views as a modest negative for Whirlpool. Pointing to even more difficult comps in the November-December period, Rehaut added that he continues to view Whirlpool's outlook of 4-6% North American industry shipment growth in 2017 as "slightly aggressive." However, he thinks this view is largely shared by investors and reflected in the stock. He maintains an Overweight rating on Whirlpool shares.
10/24/17
LOOP
10/24/17
NO CHANGE
Target $72
LOOP
Buy
Whirlpool leaving Sears positive for Best Buy, says Loop Capital
Loop Capital analyst Anthony Chukumba views Whirlpool (WHR) no longer offering appliances in Sears (SHLD) stores or online as "another incremental positive" for Best Buy (BBY). While picking up Whirlpool sales will have a "relatively insignificant impact" on Best Buy's annual earnings, Sears can no longer claim it carries all of the major U.S. appliance brands, which should accelerate its market share losses, Chukumba tells investors in a research note. He thinks Sears is "inching closer and closer" to a bankruptcy and reiterates a Buy rating on Best Buy with a $72 price target. The stock in morning trading is up 87c to $56.89.
TWTR Twitter
$22.96

-0.36 (-1.54%)

01/23/18
BARD
01/23/18
NO CHANGE
Target $20
BARD
Neutral
Noto exit may suggest Twitter turnaround moderating, says Baird
The departure of Chief Operation Officer Anthony Noto is a negative for near-term optics and could elevate concerns around Twitter's "near-term growth runway," Baird analyst Colin Sebastian tells investors in a research note. Further, the analyst believes Noto's departure toward the back-end of a multi-year turnaround effort could suggest that the pace of the company's platform improvement and monetization may be moderating. Sebastian adds, however, that management turnover within the Internet sector is not unusual. He keeps a Neutral rating on Twitter shares with a $20 price target. The stock in premarket trading is down 3.5%, or 82c, to $22.50.
01/23/18
STFL
01/23/18
NO CHANGE
Target $21
STFL
Hold
Fair to question Twitter ad business recovery after Noto loss, says Stifel
Stifel analyst John Egbert said that Anthony Noto was arguably Twitter's most outspoken advocate and was likely involved in negotiating larger advertising commitments. Given his prominent role, it is fair to question whether an advertising business recovery seems less likely now that Noto is departing, argues Egbert, who keeps a Hold rating and $21 price target on Twitter shares.
01/19/18
VERF
01/19/18
INITIATION
VERF
Negative
Twitter initiated with a Negative due to lack of ad growth at Vertical Group
01/23/18
GSCO
01/23/18
NO CHANGE
Target $32
GSCO
Buy
Twitter data points to continued improvement in engagement, says Goldman Sachs
Goldman Sachs analyst Heath Terry expects the resignation of Anthony Noto to be viewed negatively by Twitter investors, but he noted that third party data suggests that engagement within its core base continued to improve through December and his recent advertiser checks have been modestly more positive. Terry maintains his Buy rating and $32 price target on Twitter shares, which are down 40c, or about 2%, to $22.92 in morning trading.
INSM Insmed
$30.86

1.58 (5.40%)

01/18/18
FBCO
01/18/18
INITIATION
Target $31
FBCO
Neutral
Insmed initiated with a Neutral at Credit Suisse
Credit Suisse analyst Martin Auster started Insmed with a Neutral rating and $31 price target, stating that he assumes ALIS will launch around the end of 2018 with a price near the top end of anti-infective therapies but he prefers to wait for a firmer sense of how the drug will be deployed by doctors.
01/04/18
STFL
01/04/18
NO CHANGE
Target $43
STFL
Buy
New Insmed data reinforces confidence in ALIS approval, says Stifel
Stifel analyst Adam Walsh said additional interim data released by Insmed last night from its Pahse 3 program for Amikacin Liposome Inhalation Suspension, or ALIS, for adult patients with treatment refractory NTM lung disease "further bolsters" his "already high confidence" in the drug's chance for approval and commercial success. The analyst, who also noted that he does not see the company needing to raise capital in the near-term, keeps a Buy rating and $43 price target on Insmed shares.
01/04/18
BARD
01/04/18
NO CHANGE
Target $42
BARD
Outperform
Insmed price target raise to $42 from $32 at Baird
Baird analyst Brian Skorney raised his price target on Insmed to $42 from $32 following the release of positive additional data on its INS-312 drug candidate. The analyst expects an NDA to be filed by the end of Q1 versus prior guidance of by the end of the first half of the year. Skorney reiterated his Outperform rating on Insmed shares.
09/06/17
BARD
09/06/17
NO CHANGE
Target $32
BARD
Outperform
Insmed price target raised to $32 from $23 at Baird
Baird analyst Brian Skorney raised his price target on Insmed to $32 from $23 following the results of its long-awaited Phase 3 CONVERT data. The analyst noted its primary endpoints were better than expected. The secondary endpoints were not as positive, but he does not believe that will affect its approvability. Skorney reiterated his Outperform rating on Insmed shares.

TODAY'S FREE FLY STORIES

BPOP

Popular

$48.97

1.21 (2.53%)

09:51
07/23/18
07/23
09:51
07/23/18
09:51
Hot Stocks
Popular announces $125M stock repurchase plan »

Popular announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ROKU

Roku

$50.54

0.76 (1.53%)

, NFLX

Netflix

$358.65

-2.68 (-0.74%)

09:50
07/23/18
07/23
09:50
07/23/18
09:50
Recommendations
Roku, Netflix analyst commentary  »

Roku price target raised…

ROKU

Roku

$50.54

0.76 (1.53%)

NFLX

Netflix

$358.65

-2.68 (-0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

KR

Kroger

$28.78

0.64 (2.27%)

09:50
07/23/18
07/23
09:50
07/23/18
09:50
Options
Sweep buyers of Kroger short-term calls as shares see relative strength »

Sweep buyers of Kroger…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIYY

Barclays ETN+ FI Enhanced Global High Yield ETN Series B

$98.56

(0.00%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Barclays ETN+ FI Enhanced Global High Yield ETN Series B falls -5.6% »

Barclays ETN+ FI Enhanced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$42.60

-2.63 (-5.81%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Halliburton falls -5.7% »

Halliburton is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ITW

Illinois Tool Works

$136.81

-10.04 (-6.84%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Illinois Tool Works falls -6.4% »

Illinois Tool Works is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

EMES

Emerge Energy

$6.99

(0.00%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Emerge Energy rises 5.8% »

Emerge Energy is up 5.8%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

HCLP

Hi-Crush Partners

$12.90

2.05 (18.89%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Hi-Crush Partners rises 19.8% »

Hi-Crush Partners is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

DDE

Dover Downs

$3.04

1 (49.02%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Dover Downs rises 50.5% »

Dover Downs is up 50.5%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

BIDU

Baidu

$259.54

-0.46 (-0.18%)

09:45
07/23/18
07/23
09:45
07/23/18
09:45
Downgrade
Baidu rating change  »

Baidu downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 10

    Sep

MED

Medifast

$171.25

-0.21 (-0.12%)

09:45
07/23/18
07/23
09:45
07/23/18
09:45
Recommendations
Medifast analyst commentary  »

Medifast price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

09:45
07/23/18
07/23
09:45
07/23/18
09:45
General news
Existing Home Sales to be reported at 10:00 »

June Existing Home Sales…

AMZN

Amazon.com

$1,813.84

(0.00%)

09:43
07/23/18
07/23
09:43
07/23/18
09:43
Hot Stocks
Trump calls Washington Post an 'expensive lobbyist' for Amazon »

President Trump tweeted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 26

    Jul

  • 16

    Aug

ARWR

Arrowhead

$16.02

(0.00%)

09:41
07/23/18
07/23
09:41
07/23/18
09:41
Recommendations
Arrowhead analyst commentary  »

Arrowhead fair value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRNC

Tronc

$16.21

(0.00%)

09:41
07/23/18
07/23
09:41
07/23/18
09:41
Periodicals
Tronc seen making 'massive' layoffs at Daily News, NY Post reports »

The Daily News, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$10.85

(0.00%)

, HAS

Hasbro

$94.02

(0.00%)

09:40
07/23/18
07/23
09:40
07/23/18
09:40
Options
Unusually active option classes on open July 23rd »

Unusual total active…

HCLP

Hi-Crush Partners

$10.85

(0.00%)

HAS

Hasbro

$94.02

(0.00%)

DLTR

Dollar Tree

$86.45

(0.00%)

HPE

HP Enterprise

$15.47

(0.00%)

IBB

iShares Nasdaq Biotechnology Index

$118.23

(0.00%)

HAL

Halliburton

$45.23

(0.00%)

RHT

Red Hat

$147.89

(0.00%)

XLF

Financial Select Sector

$27.57

(0.00%)

BMY

Bristol-Myers

$56.71

(0.00%)

TSLA

Tesla

$313.49

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 01

    Aug

  • 01

    Aug

  • 01

    Aug

  • 07

    Aug

  • 08

    Aug

CHFS

CHF Solutions

$1.50

0.01 (0.67%)

09:38
07/23/18
07/23
09:38
07/23/18
09:38
Hot Stocks
CHF Solutions shares rise in early trade after VA contract circulated »

Shares of CHF Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPLO

Diplomat Pharmacy

$22.35

-2.575 (-10.33%)

09:35
07/23/18
07/23
09:35
07/23/18
09:35
Recommendations
Diplomat Pharmacy analyst commentary  »

Diplomat Pharmacy recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

09:35
07/23/18
07/23
09:35
07/23/18
09:35
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

09:35
07/23/18
07/23
09:35
07/23/18
09:35
General news
U.S. existing home sales preview: »

U.S. existing home sales…

UGP

Ultrapar

$11.42

0.375 (3.40%)

09:33
07/23/18
07/23
09:33
07/23/18
09:33
Downgrade
Ultrapar rating change  »

Ultrapar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZZ

Cosan

$8.32

0.105 (1.28%)

09:32
07/23/18
07/23
09:32
07/23/18
09:32
Downgrade
Cosan rating change  »

Cosan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$45.23

0.26 (0.58%)

09:32
07/23/18
07/23
09:32
07/23/18
09:32
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton says expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LPNT

LifePoint

$47.85

-0.75 (-1.54%)

, CYH

Community Health

$2.72

-0.055 (-1.99%)

09:32
07/23/18
07/23
09:32
07/23/18
09:32
Recommendations
LifePoint, Community Health, Apollo Global, HCA Healthcare analyst commentary  »

Deal activity could pick…

LPNT

LifePoint

$47.85

-0.75 (-1.54%)

CYH

Community Health

$2.72

-0.055 (-1.99%)

APO

Apollo Global

$35.39

-0.22 (-0.62%)

HCA

HCA Healthcare

$108.01

0.31 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 27

    Jul

  • 27

    Jul

  • 02

    Aug

  • 22

    Aug

BIDU

Baidu

$260.00

-2.32 (-0.88%)

09:31
07/23/18
07/23
09:31
07/23/18
09:31
Downgrade
Baidu rating change  »

Baidu downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 10

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.